Background: In this population-based cohort study involving a nationwide database from South Korea, we aimed to determine whether rapid response system (RRS) implementation is associated with mortality and morbidity after surgery under general anesthesia.
Methods: Patients who underwent surgery under general anesthesia at the hospital between January 1, 2021, and December 31, 2021. Patients admitted to hospitals with an RRS were categorized into the RRS group, whereas those without an RRS were categorized into the non-RRS group. The endpoints were 30-day mortality, 90-day mortality, and CPR performance in the event of cardiac arrest.
Results: A total of 1,416,844 patients who underwent surgery under general anesthesia were included. The RRS and non-RRS groups included 512,911 and 903,933 patients, respectively. After propensity score (PS) matching, 447,998 patients were included in both groups (223,999 patients per group). In the PS-matched cohort, compared with the non-RRS group, the RRS group had 7 % (odds ratio [OR]: 0.93, 95 % confidence interval [CI]: 0.89, 0.97; P = 0.001), 6 % (OR: 0.94, 95 % CI: 0.91, 0.97; P < 0.001), and 9 % (OR: 0.91, 95 % CI: 0.83, 0.98; P = 0.020) lower incidences of 30-day mortality, 90-day mortality, and CPR, respectively.
Conclusions: The RRS group had lower 30-day and 90-day mortality rates than the non-RRS group after surgery under general anesthesia. Moreover, RRS was associated with a lower rate of CPR episodes resulting from cardiac arrest in patients undergoing general anesthesia after surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jclinane.2025.111749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the role of MDH1 in breast cancer drug resistance through single-cell sequencing and schottenol intervention.
Cell Signal
January 2025
Department of Breast and Thyroid Surgery, The Qinghai Provincial People's Hospital, Xining 810007, China. Electronic address:
This study utilizes single-cell RNA sequencing data to reveal the transcriptomic characteristics of breast cancer and normal epithelial cells. Nine significant cell populations were identified through stringent quality control and batch effect correction. Further classification of breast cancer epithelial cells based on the PAM50 method and clinical subtypes highlighted significant heterogeneity between triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (NTNBC).
View Article and Find Full Text PDFThe Impact of Intracervical Terlipressin on Intravasation and Venous Embolization During Transcervical Myomectomy and Endometrium resection: A Randomized Controlled Study.
J Minim Invasive Gynecol
January 2025
Department of Anaesthesiology, Onze Lieve Vrouwe Gasthuis (OLVG), Oosterpark 9, 1091 AC, Amsterdam, the Netherlands.
Study Objective: To investigate whether intracervical injection of terlipressin during hysteroscopic surgery could reduce the amount of intravasation, the incidence and severity of gas embolism, and the COHb levels in the blood.
Design: Randomized double-blind controlled trial.
Setting: Gynecologic surgical unit in a general hospital.
Chapter 15: RECURRENT OR PERSISTENT PRIMARY HYPERPARATHYROIDISM, PARATHYROMATOSIS.
Ann Endocrinol (Paris)
January 2025
Department of Endocrinology Diabetes Nutrition, Hôpital Robert-Debré, CHU de Reims, F-51100 Reims, France. Electronic address:
Persistent primary hyperparathyroidism is defined as the persistence or recurrence of hypercalcemia within 6 months of parathyroid surgery. Recurrent primary hyperparathyroidism is defined as the recurrence of primary hyperparathyroidism more than 6 months after an initially curative parathyroidectomy. In these situations, it is essential to rule out differential diagnoses, and in particular secondary hyperparathyroidism and familial hypocalciuric hypercalcemia.
View Article and Find Full Text PDFChapter 6: SYNDROMIC PRIMARY HYPERPARATHYROIDISM.
Ann Endocrinol (Paris)
January 2025
Endocrinology Department, Huriez Hospital, Lille University Hospital, France. Electronic address:
Syndromic primary hyperparathyroidism has several features in common: younger age at diagnosis when compared with sporadic primary hyperparathyroidism, often synchronous or metachronous multi-glandular involvement, higher possibility of recurrence, association with other endocrine or extra-endocrine disorders, and suggestive family background with autosomal dominant inheritance. Hyperparathyroidism in multiple endocrine neoplasia type 1 is the most common syndromic hyperparathyroidism. It is often asymptomatic in adolescents and young adults, but may be responsible for recurrent lithiasis and/or bone loss.
View Article and Find Full Text PDFChapter 11: TREATMENT MODALITIES.
Ann Endocrinol (Paris)
January 2025
Internal Medicine, Diabetes and Metabolic Disorders, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
Treatment modalities for primary hyperparathyroidism must take account of the expected benefits and risks of each treatment envisaged, before choosing the definitive option to be proposed to the patient. In this section, a Foreword puts in perspective the difficulties involved in choosing the criteria for a particular treatment method. Treatments are then considered one after the other: surgery, local destruction and medical management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!